In cell and gene therapy, the moment a batch is completed is not the end of the process. In many ways, it is the beginning of a new phase. The therapy moves into storage – often at ultra-low temperatures like -196°C. It may remain there for days, weeks, or even months before reaching the patient. And during that time, one question becomes critical: Where is this patient’s therapy, and is it still viable? The Gap Between Manufacturing and Storage Over the past two decades, a clear pattern has emerged in how organizations approach digital transformation in GMP environments. The journey …